FDA Warning Letter to Joi + Blokes Over "Bioidentical" Compounded Semaglutide Claims
On June 8, 2026, FDA issued a warning letter to Joi and Blokes dba Joi + Blokes after a March 2026 review of joiandblokes.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "Joi + Blokes" as if it were the compounder "when in fact it is not," and cites claims that its products use "the same bioidentical compound as Ozempic and Wegovy," which FDA says represent unapproved compounded products as FDA-approved. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
Source: FDA original ↗